CONFIDENTIAL Protocol MT10109L -002 AMD 4
MT10109L
1Title Page
Protocol Title :A Multicenter, Double -blind , Randomized, Placebo-controlled, Parallel- group 
Study  to Evaluate the Safety  and Efficacy  of MT10109L  (Nivobotulinumtoxin A) for the 
Treatment of Lateral Canthal Lines
Protocol Number :MT10109L -
002
Amendment Number: Amendment 4
Product :MT10109L ( NivobotulinumtoxinA )
Brief Protocol Title: MT10109L  in the Treatment of Lateral Canthal Lines
Development Phase: 3
Regulatory Agency Identifying Numbers: IND Number 121473;
EudraCT Number 2014-005279-10
Refer to the final page of this protocol for electronic signature and date of approval.
Approval Date: 30-Sep-2020 22:56:17 (GMT)

CONFIDENTIAL Protocol MT10109L -002 AMD 4
MT10109L
8
Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

CONFIDENTIAL Protocol MT10109L -002 AMD 4
MT10109L
225. Study Population
Participa nts in the current study  have moderate to severe LCL at maximum smile ,as specified in 
Section 5.1.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

306.2. Preparation/Handling/Storage/Accountability
1.The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and an y discrepancies are 
reported and resolved before use of the stud y intervention .
2.Only  participants enrolled in the study  may  recei ve study  intervention, and only  authorized 
site personnel may administer study  intervention. All study  intervention must be stored in a 
secure ,environmentall y controlled, and monitored (manual or automated) area in accordance 
Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

CONFIDENTIAL Protocol MT10109L -002 AMD 4
MT10109L
5810.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representat ive and answer all questions regarding the 
study .
Participants must be informed that their participation is v oluntary . Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, HI PAA requirements, where applicable , and the IRB/IEC 
or study  center.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtained. 
The authorized person obtaining the informed consent must also sign the ICF.
Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study .
A cop y of the ICF(s)must be provided to the participant or the participant’s leg ally 
authorized representative.
Participants who are rescreened are required to sign a new ICF.
10.1.4. Data Protection
Participants will be assigned a unique identifier. Any participant records or datasets that are 
transferred to the sponsor will contain the identifier only ; participant names or any  
information which would make the participant identi fiable will not be transferred.
The participant must be informed that his/her personal study -related data will be used by  the 
sponsor in acco
rdance with local data protection law. The level of disclosure must also b e 
explained to the participant.
The participant must be informed that his/her medi cal records may  be examined by  clinical 
quality  assurance auditors or other authorized personnel appointed by  the s ponsor, by  
appropriate IRB/IEC members, and b y inspectors from regulatory authorities.
10.1.5. Posting Clinical Study Data
Study  data and information may  be published in nonpromotional, peer -reviewed publications 
either b y or on behalf of the sponsor. 
Clinical study  reports, safety  updates, and annual reports will be provided to regulatory  
authorities as required.
Company -sponsored study  information and tabular study  results will be posted on the US 
National Institutes of Health's website www.ClinicalTrials.gov and other publicly  accessible 
sites
Approval Date: 30-Sep-2020 22:56:17 (GMT)

CONFIDENTIAL Protocol MT10109L -002 AMD 4
MT10109L
5910.1.6. Data Quality Assurance
All participant data relating to the stud y will be re corde d on printed or e CRF s unless 
transmitted to the sponsor or designee electronically  (eg,laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the e
CRF.
The investi gator must maintain accurate documentation (source data) that supports the 
information entered inthe eCRF.
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections andprovide direct a ccess to source data documents.
The sponsor or designee is responsible for the data management of this study includin g 
quality  checking of the data.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the e CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety  and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, ICH GCP, and all applicable regulator y requirements.
Records and documents, including signed ICFs , pertaining to the conduct of this study  must 
be retained b y the investigator as stated in the clinical trial agreement. No records may  be 
destroy ed during 
the retention period without the written approval of the sponsor . No records 
may be transferred to another location or party  without written notification to the sponsor .
10.1.7. Source Documents
Source documents provide evidence for the existence of the participan t and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the di
screpancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study .
Definition of what constitutes source data can be found in Section 4.0 of I CH E6, Good 
Clinical Practice: Consolidated Guidance and must follow ALCOA, ie, records must be 
attributable, legible, contemporaneous, original, and accurate.
10.1.8. Study and Site Closure
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  supplies 
have been collected and a study -site closure visit has been performed .
Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

CONFIDENTIAL Protocol MT10109L -002 AMD 4
MT10109L
9410.10. Appendix 10: Protocol Amendment History
The protocol amendment summary  of changes table for the current amendment is located 
directly  before the table of contents.
Approval Date: 30-Sep-2020 22:56:17 (GMT)

Approval Date: 30-Sep-2020 22:56:17 (GMT)

Electronic Signatures
User Date Justification
Approval Date: 30-Sep-2020 22:56:17 (GMT)
